These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 10992179

  • 1. Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis.
    Heald A, Selby PL, White A, Gibson JM.
    Am J Obstet Gynecol; 2000 Sep; 183(3):593-600. PubMed ID: 10992179
    [Abstract] [Full Text] [Related]

  • 2. Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk.
    Heald A, Kaushal K, Anderson S, Redpath M, Durrington PN, Selby PL, Gibson MJ.
    Gynecol Endocrinol; 2005 Mar; 20(3):176-82. PubMed ID: 16019358
    [Abstract] [Full Text] [Related]

  • 3. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy.
    Simon JA, Liu JH, Speroff L, Shumel BS, Symons JP.
    Am J Obstet Gynecol; 2003 Jan; 188(1):92-9. PubMed ID: 12548201
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Progestins affect mechanism of estrogen-induced C-reactive protein stimulation.
    Reuben DB, Palla SL, Hu P, Reboussin BA, Crandall C, Herrington DM, Barrett-Connor E, Greendale GA.
    Am J Med; 2006 Feb; 119(2):167.e1-8. PubMed ID: 16443423
    [Abstract] [Full Text] [Related]

  • 6. Plasma insulin-like growth factor-I and its binding proteins 1 and 3 during continuous nonoral and oral combined hormone replacement therapy.
    Raudaskoski T, Knip M, Laatikainen T.
    Menopause; 1998 Feb; 5(4):217-22. PubMed ID: 9872487
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
    Keramaris NC, Christodoulakos GE, Lambrinoudaki IV, Dalamanga A, Alexandrou AP, Bramis J, Bastounis E, Creatsas GC.
    Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143
    [Abstract] [Full Text] [Related]

  • 13. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
    Pluchino N, Genazzani AD, Bernardi F, Casarosa E, Pieri M, Palumbo M, Picciarelli G, Gabbanini M, Luisi M, Genazzani AR.
    Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
    [Abstract] [Full Text] [Related]

  • 14. The IGF system in the neonatal ovine uterus.
    Hayashi K, Carpenter KD, Welsh TH, Burghardt RC, Spicer LJ, Spencer TE.
    Reproduction; 2005 Mar; 129(3):337-47. PubMed ID: 15749960
    [Abstract] [Full Text] [Related]

  • 15. Cyproterone, norethindrone, medroxyprogesterone and levonorgestrel are less potent local human growth hormone and insulin-like growth factor I secretion stimulators than progesterone in human breast cancer explants expressing the estrogen receptor.
    Milewicz T, Kolodziejczyk J, Krzysiek J, Basta A, Sztefko K, Kurek S, Stachura J, Gregoraszczuk EL.
    Gynecol Endocrinol; 2002 Aug; 16(4):319-29. PubMed ID: 12396561
    [Abstract] [Full Text] [Related]

  • 16. Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study.
    Taner MZ, Ozpolat E, Taskiran C, Onan MA, Gursel T, Karabulut E, Gursoy R, Himmetoglu O.
    Maturitas; 2006 Feb 20; 53(3):267-73. PubMed ID: 15978753
    [Abstract] [Full Text] [Related]

  • 17. Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene.
    Christodoulakos G, Lambrinoudaki I, Panoulis C, Sioulas V, Rizos D, Caramalis G, Botsis D, Creatsas G.
    Maturitas; 2005 Apr 11; 50(4):321-30. PubMed ID: 15780533
    [Abstract] [Full Text] [Related]

  • 18. Estrogen, progestogens and cardiovascular risk.
    Stefanick ML.
    J Reprod Med; 1999 Feb 11; 44(2 Suppl):221-6. PubMed ID: 11392036
    [Abstract] [Full Text] [Related]

  • 19. A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers.
    Decensi A, Bonanni B, Baglietto L, Guerrieri-Gonzaga A, Ramazzotto F, Johansson H, Robertson C, Marinucci I, Mariette F, Sandri MT, Daldoss C, Bianco V, Buttarelli M, Cazzaniga M, Franchi D, Cassano E, Omodei U.
    Clin Cancer Res; 2004 Jul 01; 10(13):4389-97. PubMed ID: 15240527
    [Abstract] [Full Text] [Related]

  • 20. Progestins and estrogens and Alzheimer's disease.
    Honjo H, Iwasa K, Kawata M, Fushiki S, Hosoda T, Tatsumi H, Oida N, Mihara M, Hirasugi Y, Yamamoto H, Kikuchi N, Kitawaki J.
    J Steroid Biochem Mol Biol; 2005 Feb 01; 93(2-5):305-8. PubMed ID: 15860274
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.